Trial · NCT07877324
Vascular Inflammation in Atherosclerosis - Whole Body Molecular PET/CT Imaging Using Folate Receptor β
NCT07877324, Not applicable, Recruiting, Turku University Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Vascular Inflammation in Atherosclerosis - Whole Body Molecular PET/CT Imaging Using Folate Receptor β. Trials, record NCT07877324. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07877324
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Vascular Inflammation in Atherosclerosis - Whole Body Molecular PET/CT Imaging Using Folate Receptor β
- NCT number
- NCT07877324
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 90 participants, estimated
- Lead sponsor
- Turku University Hospital
- Conditions
- Atheroscleroses, Inflammation
- Interventions
- 18F-AlF-NOTA-Folate PET
- First posted
- 2026-10-16
- Last updated
- 2026-10-16
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Coronary 18F-AlF-NOTA-Folate uptake measured by a target-to-background ratio | At Visit 2, approximately 1-4 weeks after Visit 1 | Quantification of 18F-AlF-NOTA-Folate uptake in the main coronary arteries (LAD, LCX, RCA) using target-to-background ratio (TBR). TBR is a dimensionless ratio of coronary tracer uptake (SUVmax) to background blood-pool activity (SUVmean). Coronary uptake and blood-pool activity will be quantified using whole-vessel three-dimensional volumes of interest derived from coronary CT angiography and analyzed using FusionQuant software. Measurements will be reported per coronary vessel. |
| Primary | 18F-AlF-NOTA-Folate uptake in extracardiac arteries measured by TBR | At Visit 2, approximately 1-4 weeks after Visit 1 | Quantification of 18F-AlF-NOTA-Folate uptake in the carotid arteries, aorta, and iliac arteries using target-to-background ratio (TBR). TBR is a dimensionless ratio of arterial wall tracer uptake (SUVmax) to background activity (SUVmean). Tracer uptake and blood poll activity will be measured in volumes of interest on co-registered PET and CT images using an in-house developed automated analysis tool. TBR will be reported per vessel (carotid arteries, aorta, iliac arteries). |
| Secondary | Correlation between coronary 18F-AlF-NOTA-Folate uptake and coronary plaque characteristics | At Visit 2, approximately 1-4 weeks after Visit 1 | Correlation between coronary 18F-AlF-NOTA-Folate uptake, measured target-to-background ratio (TBR; dimensionless), and coronary plaque characteristics measured by coronary CT angiography using an artificial intelligence-based quantitative computed tomography (AI-QCT) algorithm. Coronary plaque characteristics include plaque volume (mm³), percentage plaque per vessel (%) calculated as plaque volume divided by vessel volume, and plaque type/classification (calcified/non-calcified). Correlations will be reported separatety for each main coronary vessel and plaque variable. |
| Secondary | Correlation between extracardiac arterial 18F-AlF-NOTA-Folate uptake and plaque characteristics | Visit 2, approximately 1-4 weeks after Visit 1 | Correlation between 18F-AlF-NOTA-Folate uptake in the carotid arteries, aorta, and iliac arteries, measured using target-to-background ratio (TBR; dimensionless), and plaque characteristics measured by contrast-enhanced CT angiography. Plaque characteristics will be assessed automatically using comercially available software (Mosaic by Navier medical). Plaque characteristics include plaque volume (mm³), percentage plaque per vessel (%) calculated as plaque volume divided by vessel volume, and plaque type/classification (calcified/non-calcified). Correlations will be reported separatety for each vessel and plaque variable. |
| Secondary | 18F-AlF-NOTA-Folate uptake in bone marrow and spleen measured by TBR | Visit 2, approximately 1-4 weeks after Visit 1 | Quantification of 18F-AlF-NOTA-Folate uptake in the bone marrow of the lumbar vertebral bodies and spleen using target-to-background ratio (TBR). TBR is a dimensionless ratio of tissue tracer uptake in bone marrow and spleen (SUVmax) to blood background activity (SUVmean). Measurements will be performed in co-registered PET and CT images using an in-house developed automated analysis tool. TBR will be reported separately for bone marrow and for spleen. |
| Secondary | Correlation between bone marrow and spleen 18F-AlF-NOTA-Folate uptake and blood biomarkers of inflammation | Visit 2, approximately 1-4 weeks after Visit 1 | Correlation between 18F-AlF-NOTA-Folate uptake in the bone marrow and spleen, measured using target-to-background ratio (TBR), and blood concentrations of high-sensitivity C-reactive protein (hsCRP). hsCRP concentration will be measured in mg/L using blood samples collected before the 18F-AlF-NOTA-Folate PET scan. The correlations between tracer uptake (TBR) and hsCRP will be assessed separately for bone marrow and for spleen. |
| Secondary | Time to first major cardiovascular clinical event | Up to 5 years after inclusion | Time from study inclusion to the first occurrence of the composite of all-cause death, non-fatal myocardial infarction, unstable angina, late coronary revascularization by percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) occurring more than 6 months after study inclusion, ischemic stroke or transient ischemic attack (TIA), or peripheral revascularization for claudication or ischemia. The outcome will be measured as time from study inclusion to the first qualifying event, in months. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07877324
GET https://conductscience.org/api/trials/v1/NCT07877324/registered